Numeral 11 — NOM-037-SSA2-2012, Para la prevención, tratamiento y control de las dislipidemias

11 Bibliografía

11.1. Aguilar-Salinas CA, Mehta R, Rojas R, Gómez-Pérez FJ, Olaiz G, Rull JA. Management of the

metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 Diabetes:

controversial issues. Current Diabetes Reviews 2005:1: 145-158.

11.2. Aguilar Salinas CA, Gómez Pérez FJ, Lerman I, Pérez O, Posadas C. Diagnóstico y tratamiento de

las Dislipidemias; Postura de la Sociedad Mexicana de Nutrición y Endocrinología. Revista de Endocrinología

y Nutrición. 2004; 12: 7-41.

11.3. Alcocer L, Parra JZ, Hernández HH. Versión mini malista del tratamiento antihipertensor. Rev Mex

Cardiol 2008; 19 (1):3-6.

11.4. American Dietetic Association: Use of nutritive and nonnutritive sweeteners (Position statement). J

Am Diet Assoc. 1993; 93: 816-21.

11.5. Appel LJ, Moore TJ, Obarzanek E, et al. For the DASH Collaborative Research Group. A clinical trial

of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336:1117-1124.

11.6. Barriguete-Meléndez JA., Aguilar-Salinas CA, Barq uera S, Pérez A, Lara A, Hernández-Avila M,

Córdova-Villalobos JA. Motivación y Adherencia al Tratamiento a Largo Plazo. Enfermedad Crónica:

Dislipidemias ALGORRITMO 1 Conocer. 2 Hacer y 3 Evaluar. En: S Barquera e I Campos (Eds) Dislipidemias,

epidemiología, evaluación y adherencia y tratamiento. Cuernavaca, México INSP. 2007: en prensa.

11.7. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of

hypertension in the adult US popul ation: data from the health exam ination surveys, 1960 to 1991.

Hypertension 1995; 26:60-69.

11.8. III Consenso Nacional de Hipertensión Arterial Sistémica, Rev Mex Cardiol 2005; 16(1): 5-47.

11.9. Córdova-Villalobos JA, Barriguete-Meléndez, JA, Lara-EsquedaA, Barquera S, Rosas PM,

Hernández AM, León-May ME, Vivanco JA Aguilar-SC. Las enfermedades crónico-degenerativas: un reto al

sistema de salud con alternativas de solución, la "prevención clínica".

11.10. Du X Cruickshank K, McNamee R, et al. Case control study of stroke and the quality of hypertension

control in Northwest England. BMJ 1997; 314:272-276.

11.11. European Society of Hypertension, European Society of Cardiology. 2007 Guidelines for the

management of arterial hypertension. European Heart Journal 2007; 28:1462-1536.

11.12. Guía de ejercicios para la prevención de padecimientos crónico degenerativos para personas de 51

a 70 años. Secretaría de Salud. Salud 2000. Promoción de la Salud. p. 39.

11.13. Guyatt GH, Sackett DI, Sinclair JC , Hayward R, Cook DJ, Hayward R, Cook DJ, Cood RJ. For the

medical literature. IX. A method for grading health care recommendations JAMA 1995; 274:1800-1804.

11.14. Hall WD, Ferrario CM, Moore MA, et al. Hypert ension-related morbidity and mortality in the

Southeastern United States. Am J Med Sci 1997; 313: 195-206.

11.15. Haynes RB, et al. Systematic review of randomized trials of interventions to assist patients to follow

prescriptions for medications. Lancet 1996; 348:383-386.

11.16. Hernández-y-Hernández H, Meaney-Mendiolea E, Navarro-Robles J. III Consenso Nacional de

Hipertensión Arterial Sistémica, Rev Mex Cardiol 2005; 16(1): 5-47.

11.17. Kaplan N. Clinical hypertension. Baltimore Md. USA Williams and Wilkins (6a. edition) 1994.

11.18. Lara Esqueda A, Aroch Calderón A, Jiménez RA, Arceo Guzmán M, Velázquez Monroy O. Grupos

de Ayuda Mutua: Estrategia para el c ontrol de Diabetes e hipertensión arte rial. Archivos de Cardiología de

México. 2004; 74 (4): 330-336.

11.19. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. For the Modification of Diet in Renal Disease

Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of

Diet in Renal Disease Study Group. Hypertension 1997; 29:641-650.

11.20. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to

congestive heart failure. JAMA 1996; 275:1557-1562.

11.21. Ley Federal sobre Metrología y Normalización. Congreso General de los Estados Unidos

Mexicanos. México.

11.22. Ley General de Salud. Congreso General de los Estados Unidos Mexicanos. México.

11.23. Luepker RV, McGovern PG, Sprafka JM, Shahar E, Doliszny KM. Blackburn H. Unfavorable trends

in the detection and treatment of hypertension: the Minnesota Heart Survey (abstract). Circulation 1995;

91:938.

11.24. Manual de todo corazón. Ejercicios para la prevención de afecciones cardiovasculares e

hipertensión arterial para personas de 30 a 50 años de edad. Secretaría de Salud. Dirección General de

Promoción de la Salud. p. 26.

11.25. Morbilidad y mortalidad de la enfermedad isquémica del corazón y Cerebrovascular en México.

2005 Oscar Velázquez Monroy, Fernando S Barinagarrem entería Aldatz, Alberto Francisco Rubio Guerra,

Juan Verdejo, Miguel Angel Méndez Bello, Rafael Viol ante, Abel Pavía, Ricardo Alvarado-Ruiz, Agustín Lara

Esqueda. Vol. 77 Número 1/Enero-Marzo 2007:31-39 Archivos de Cardiología de México.

11.26. MRC Working Party. Medical Research Council tria l of treatment of mild hypertension. Principal

results. BMJ 1985; 291:97-104.

11.27. National High Blood Pressure Education Program. Working Group Report on Primary Prevention of

Hypertension. US. Deparment of Health and Human Services. National Institutes of Health; NIH Publication No

93-2669; 1993.

11.28.

National Heart, Lung, and Blood Institute. The Sports Guide: NHLBI Planning Guide for

cardiovascular Risk Reduction Projects at Sporting Events. Bethesda , MD: U.S. Department of Health and

Human Services, National Institutes of Health; NIH publication No. 95-3802; 1995.

11.29. National High Blood Pressure Education Program Working Group. National High Blood Pressure

Education Program working group report on hypertension in the elderly. Hypertension 1994; 23:275-285.

11.30. Neaton JD, Grimm RH Jr, Prineas RS, et al. Fo r the Treatment of M ild Hypertension Study

Research Group. Treatment Mild Hypertension Study: Final Results. JAMA 1993; 270: 713-724.

11.31. Neispeira Blanco A. 1000 ejercicios de preparación física. Vol. 1. 2a Edición p. 204. Lleida, España.

11.32. Nesselroad JM, Flacco VA, Phillips DM, Kruse J. Accuracy of automated finger blood pressure

devices. Fam Med 1996; 28 189-192.

11.33. Noyes MA. Pharmacotherapy for elderly women. J Am Med Women's Assoc 1997;52: 138-158.

11.34. Pickering T. For an American Society of Hypert ension ad hoc Panel. Recommendations for the use

of home (self) and ambulatory blood pressure monitoring. Am J Hypertens 1995; 9:1-11.

11.35. Prisant LM, Alpert BS, Robbins CB, et al. American National Standard for nonautomated

sphygmomanometers: summary report. Am J Hypertens 1995; 8:210-213.

11.36. Proyecto Muévete. Manual del personal de salud. Evaluación y orientación referente a la actividad

física. OPS/OMS Centros para la prevención y control de enfermedades de E.U.A.

11.37. Rojas R, Aguilar-Salinas CA, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G, Sepúlveda J, Rull J.

Applicability of the Nation al Cholesterol Education Program III ( NCEP-III) Guidelines for treatment of

dyslipidemia in a non-Caucasian population: A Mexican Nation- Wide Survey. Revista de Investigación Clínica

2005; 57:28-37.

11.38. Rosas-Peralta M, Lara-Esqueda A, Pastelin-Hernández G, Velázquez-MO, Martínez-Reding J,

Méndez-Ortiz A et al. Re-encuesta Nacional de Hiperte nsión Arterial (RENAHTA): Consolidación Mexicana de

los factores de riesgo cardiovascular. Cohorte nacional de seguimiento. Arch Cardiol Mex. 2005; 75:96-111.

11.39. Samperio J. Actividad Física y deporte en el adulto mayor. Bases fisiológicas. Edit. Masson Doyma.

México, 1a. Edición.

11.40. Secretaría de Salud. Programa Sectorial de Salud. 2007-2012. Disponible en:

http://www.alianza.salud.Gob.mx/descargas/pdf/pns_version_completa.pdf

11.41. Secretaría de Salud. Sistema de Vigilancia Epidemiológica Hospitalaria de Diabetes tipo 2. DGE-SS

2004-2006.

11.42. Stamler J, Stamler R, Neaton JD. Blood pressure , systolic and diastolic, and cardiovascular risks.

US population Data. Arch Intern Med 1993, 153: 598-615.2004. p.p 121.

11.43. Stamler J, Caggiula AW, Grandits GA. Chapter 12. Relation of body mass and alcohol, nutrient,

fiber, and caffeine intakes to blood pressure in the spec ial intervention and usual care groups in the Multiple

Risk Factor Intervention Trial. Am J Clin Nutr 1997; 65 (suppl): 338S-3655.

11.44. The CDC Diabetes Cost-effectiveness Group. Cost-e ffectiveness of intensive glycemic control,

intensified hypertension control, a nd serum cholesterol reduction for type 2 Diabetes. JAMA 2002; 287:2542-

2551.

11.45. Trials of Hypertension Prevention Collaborative Re search Group. Effects of weight loss and sodium

reduction intervention on blood pressure and hypertens ion incidence in overweight people with high normal

blood pressure: the Trials of Hypertension Prevention, phase II Arch Intrn Med 1997; 157:657-667.

11.46. Tsuji I, Imai Y, Nagai K, et al. Proposal of re ference values for home blood pressure measurement:

prognostic criteria based on a pros pective observation of the general popu lation in Ohasama, Japan. Am J

Hypertens 1997, 10:409-418.

11.47. Whelton PW, Applegate WB, Ettinger WH, et al. Efficacy of weight loss and reduced sodium intake

in the Trial of Nonpharmacologic Interventions in the El derly (TONE). (Abstract) Circulation 1996; 94 (suppl. l):

1-178.

11.48. WHO Expert Committee on Hypertension Control. Hypertension Control: Report of a WHO Expert

Committee.Technical Report Series No. 862, Geneva, Switzerland: World Health Organization; 1996.

11.49. Winberg N, et al. 24-H ambulatory blood pressure in 352 normal Danish subjects related to age and

gender. Am J Hypertens 1995; 8:978-986.